Welcome to eBiochemicals.
Directory
| Smiles | C[[email protected]@]12C(N3C=NC4=CC=CC=C34)=CC[[email protected]]1([[email protected]@]5(CC=C6[[email protected]@](C)([[email protected]]5(CC2)[H])CC[[email protected]@H](C6)O)[H])[H] |
|---|---|
| Synonyms | VN/124-1; Galeterone; VN 124;TOK001;TOK 001; (3S,8R,9S,10R,13S,14S)-17-(1H-benzo[d]imidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| InChI | InChI=1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3/t18-,19-,20-,21-,25-,26-/m0/s1 |
TOK-001 (VN/124-1; Galeterone) is a multifunctional antiandrogen and CYP17 inhibitor(IC50=47 nM) in castration resistant prostate cancer (CRPC). IC50 value: 47 nM Target: CYP17 TOK-001 and abiraterone reduced AR protein and mRNA expression, and antagonized AR-dependent promoter activation induced by androgen.
| Galeterone (TOK-001, VN/124-1) is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively. Galeterone is effective at preventing binding of [3H]-R1881 (methyltrienolone, a stable synthetic androgen) to both the mutant AR (T877A) in LNCaP cells and the wild-type AR in PC-3AR cells. Galeterone potently inhibits the AR-mediated transcription in LNCaP cells transiently transfected with a probasin luciferase reporter construct AARZ-Luc in a concentration-dependent manner. Galeterone inhibits the growth of DHT-stimulated LNCaP and LAPC4 prostate cancer cells with IC50 of <10 μM. Galeterone is very effective at inhibiting the growth of androgen-dependent LAPC4 human prostate tumor xenograft. In the LAPC4 xenograft, Galeterone is a more potent agent in reducing tumor growth than other compounds (VN/85, VN/87, and VN108) and is more effective than castration and casodex. Treatment with Galeterone markedly reduces AR protein levels both in vivo and in vitro. Thus, Galeterone disrupts androgen receptor (AR) signaling via a novel triple mechanism of action (CYP17 inhibition, competitive inhibition, and down-regulation of the AR). Galeterone also inhibits the growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Additionally, Galeterone in combination with thapsigargin exhibits synergistic effect in inhibiting PC-3 cell growth. Galeterone in combination with everolimus or gefitinib demonstrates superior synergy for growth inhibition against hormone-refractory prostate cancer cell line (high-passage LNCaP, HP-LNCaP) compared with bicalutamide. Dual inhibition of AR and mTOR with Galeterone and everolimus acts in concert to reduce tumor growth rates in the castration-resistant prostate cancer xenograft model. Galeterone is a superior inhibitor than abiraterone of R1881-induced transcriptional activity of both wild type and mutant AR. ......by AbMole BioScience |
| TOK-001 (Galeterone) is both an androgen receptor antagonist and CYP17A1 inhibitor. ......by AdooQ BioScience, LLC |
| Description ......by Apexbio Technology LLC |
| Galeterone?(TOK-001?or?VN/124-1) is a novel?antiandrogen?under development by?Tokai Pharmaceuticals?for the treatment of?prostate cancer. It possesses a unique dual?mechanism of action, acting as both anandrogen receptor?antagonist?and an?inhibitor?of?CYP ......by BOC Sciences |
| TOK-001 is a multifunctional antiandrogen and CYP17 inhibitor (IC50=47 nM) in castration resistant prostate cancer (CRPC). ......by MedChemexpress Co., Ltd. |
| Galeterone, also known as TOK-001 and NX41765; is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. ......by MedKoo Biosciences, Inc. |
| A potent 17α-hydroxylase/17,20-lyase (CYP17) inhibitor with IC50 of 300 nM; also shown to be potent pure AR antagonist; inhibits the growth of DHT-stimulated LNCaP and LAPC4 prostate cancer cells with IC50 <10 uM; causes marked down-regulation of AR protein expression, more efficacious than castration in the LAPC4 xenograft model.Prostate CancerPhase 3 Clinical ......by ProbeChem |
| Galeterone is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively, and is a potent inhibitor of human prostate tumor growth. Phase 2. ......by Selleck Chemicals LLC |
| Galeterone is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively, and is a potent inhibitor of human prostate tumor growth. Phase 2. ......by Target Molecule Corp. |
| CYP17 inhibitor (IC50 = 300 nM) and androgen receptor antagonist (IC50 = 384 nM in PC3-AR cells). Inhibits DHT-stimulated prostate cancer cell proliferation in vitro. Exhibits antitumor activity in SCID mice bearing prostate cancer xenografts. ......by Tocris Bioscience Inc. |
| Animal Models | Male severe combined immunodeficient (SCID) mice inoculated subcutaneously (s.c.) with LAPC4 cells |
|---|---|
| Dosage | 50 mg/kg |
| Formulation | Prepared at 17.2 mg/mL in a 0.3% solution of hydroxypropyl cellulose in saline |
| Administration | Injection s.c. twice daily |
| Source | Selleck Chemicals LLC |
| Appearance:White to off-white solid | EBNumber:EB000028832 |
| DMSO | by MedChemexpress Co., Ltd. |
| (25°C) * In vitro DMSO 24 mg/mL (61.76 mM); Ethanol40 mg/mL warming (102.94 mM); Water<1 mg/mL (<1 mM); In vivo 0.5% hydroxyethyl cellulose30 mg/mL | by Selleck Chemicals LLC |
| Signaling Pathways | Metabolic Enzyme/Protease |
|---|
| Target | Cytochrome P450 |
|---|
| Research Area | Cancer |
|---|
| Indications | Hormone refractory prostate cancer | Hormone refractory prostate cancer |
|---|
| Product Name | Sponsor & Collaborators | Indications | Start Date | End Date | Phase |
|---|---|---|---|---|---|
| TOK-001 | Tokai Pharmaceuticals Inc | Hormone refractory prostate cancer | 2012/12/31 | 2014/9/30 | Phase 2 Clinical |
| TOK-001 | Tokai Pharmaceuticals Inc | Hormone refractory prostate cancer | 2009/10/31 | 2012/8/31 | Phase 1 Clinical |
| TOK-001 | - | Phase 3 |
| Company | Price and Availability | Country/Region |
|---|---|---|
| AA Blocks LLC | ||
| AbMole BioScience | USA | |
| AdooQ BioScience, LLC | USA | |
| Apexbio Technology LLC | USA | |
| Ark Pharm, Inc. | USA | |
| BLD Pharmatech | ||
| BOC Sciences | ||
| Biochempartner Co., Ltd | China | |
| CHEMSCENE, LLC | 5mg/USD60();10mg/USD90() | USA |
| Cayman Chemical Company | USA | |
| MedChemexpress Co., Ltd. | 5mg/USD60();10mg/USD90() | USA |
| MedKoo Biosciences, Inc. | USA | |
| ProbeChem | ||
| Pure Chemistry Scientific Inc. | 5mg/USDnull(In stock) | USA |
| Selleck Chemicals LLC | 5mg/USD170(In stock);10mM/1mLIn DMSO/USD260(In stock);25mg/USD470(In stock);50mg/USD670(In stock);200mg/USD1670(In stock) | USA |
| Shanghai Haoyuan Chemexpress Co., Ltd. | 5mg/USD60();10mg/USD90() | China |
| Target Molecule Corp. | 5mg/USD97();10mg/USD171();50mg/USD528() | USA |
| Tocris Bioscience Inc. | USA |
| Name | CAS No | Formula | MW |
|---|
| Name | CAS No | Formula | MW |
|---|---|---|---|
| Dafadine-A | 1065506-69-5 | C23H25N3O3 | 391.46 |
| VT-464 (racemate) | 1375603-36-3 | C18H17F4N3O3 | 399.34 |
| VT-464 | 1610537-15-9 | C18H17F4N3O3 | 399.34 |
| Isosilybin | 72581-71-6 | C25H22O10 | 482.44 |
| Memantine (hydrochloride) | 41100-52-1 | C12H22ClN | 215.76 |
| Clarithromycin | 81103-11-9 | C38H69NO13 | 747.95 |
| (+)-Ketoconazole | 142128-59-4 | C26H28Cl2N4O4 | 531.43 |
| (+)-Ketoconazole | 142128-59-4 | C26H28Cl2N4O4 | 531.4309 |
| Galangin | 548-83-4 | ||
| Bergapten | 484-20-8 | C12H8O4 | 216.19 |
| Naringin | 10236-47-2 | C27H32O14 | 580.53 |
| Diosmetin | 520-34-3 | C16H12O6 | 300.26 |
| Fenofibrate | 49562-28-9 | C20H21ClO4 | 360.83 |
| Bergaptol | 486-60-2 | C11H6O4 | 202.1629 |
| Talarozole (R enantiomer) | 870093-23-5 | C21H23N5S | 377.5058 |
| Choline Fenofibrate | 856676-23-8 | C22H28ClNO5 | 421.91 |
| Talarozole | 201410-53-9 | C21H23N5S | 377.51 |
| Isavuconazole | 241479-67-4 | C22H17F2N5OS | 437.4650864 |
| Cobicistat | 1004316-88-4 | C40H53N7O5S2 | 776.02 |
| Methoxsalen | 298-81-7 | C12H8O4 | 216.19 |
| Name | CAS No | Formula | MW |
|---|---|---|---|
| TAK-700 (R-form) | 752243-39-3 | C18H17N3O2 | 307.35 |
| Olaparib | 763113-22-0 | C24H23FN4O3 | 434.46 |
| KX2-391 | 897016-82-9 | C26H29N3O3 | 431.53 |
| Bicalutamide | 90357-06-5 | C18H14F4N2O4S | 430.37 |
| Enzalutamide | 915087-33-1 | C21H16F4N4O2S | 464.44 |
| Linsitinib | 867160-71-2 | C26H23N5O | 421.49 |
| Fenretinide | 65646-68-6 | C26H33NO2 | 391.55 |
| Retaspimycin | 857402-23-4 | C31H45N3O8 | 587.7 |
| Retaspimycin (Hydrochloride) | 857402-63-2 | C31H46ClN3O8 | 624.17 |
| Bafetinib | 859212-16-1 | C30H31F3N8O | 576.6154 |
| AT13387 | 912999-49-6 | C24H31N3O3 | 409.52 |
| Tasquinimod | 254964-60-8 | C20H17F3N2O4 | 406.36 |
| Orteronel | 566939-85-3 | C18H17N3O2 | 307.35 |
| Orteronel (racemate) | 426219-18-3 | C18H17N3O2 | 307.3465 |
| TAK-700 (salt) | 426219-53-6 | C28H28N4O7 | 532.54 |
| Cabozantinib | 849217-68-1 | C28H24FN3O5 | 501.51 |
| Odanacatib | 603139-19-1 | C25H27F4N3O3S | 525.56 |
| Zibotentan | 186497-07-4 | C19H16N6O4S | 424.43 |
| Danusertib | 827318-97-8 | C26H30N6O3 | 474.55 |
| Atrasentan | 173937-91-2 | C29H38N2O6 | 510.62 |
